Clinical trials in sepsis: an update.

Area of Science:

• Critical Care Medicine
• Immunology
• Pharmacology

Background:

• Sepsis remains a leading cause of mortality, necessitating novel therapeutic strategies.
• Decades of clinical trials have explored various agents to modulate the host response in sepsis.
• Understanding the efficacy and safety of these interventions is crucial for improving patient outcomes.

Purpose of the Study:

• To contextualize recent sepsis clinical trials within the landscape of research from the past three decades.
• To evaluate the effectiveness and safety of agents targeting host proinflammatory mediators, corticosteroids, and nitric oxide production in sepsis.

Main Methods:

• Review and analysis of clinical sepsis trials conducted over the last year and preceding thirty years.
• Focus on trials investigating agents to limit tumor necrosis factor, platelet-activating factor, prostaglandins, corticosteroids, and nitric oxide synthase inhibitors.

Main Results:

• Trials of agents targeting proinflammatory mediators demonstrated minimal benefits, consistent with previous findings.
• Low-dose corticosteroids showed potential in reversing shock with non-significant survival trends.
• High-dose corticosteroids administered early in sepsis exhibited detrimental effects.
• High-dose inhibition of nitric oxide production proved lethal in septic shock.

Conclusions:

• Agents targeting specific host proinflammatory mediators have consistently shown limited efficacy in sepsis treatment.
• Low-dose corticosteroids warrant further investigation for their potential role in sepsis management.
• High-dose corticosteroids and nonspecific nitric oxide synthase inhibitors are contraindicated in septic shock due to adverse effects.